



COPY OF PAPERS
ORIGINALLY FILED

Docket No. 2026-4230US1

**RESPONSE UNDER 37 C.F.R. §1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1644**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): J. SHLOM et al.

Group Art Unit: 1644

Serial No.: 09/155,590

Examiner: G. Ewoldt

Filed: September 30, 1998

For: **MUTATED RAS PEPTIDES FOR GENERATION OF CD8+ CYTOTOXIC T
LYMPHOCYTES**

RECEIVED
APR 26 2002
TECH CENTER 1600/2900

AMENDMENT AND RESPONSE TO THE FINAL OFFICE ACTION
MAILED JANUARY 14, 2002

Commissioner for Patents
Washington, DC 20231 BOX: AF

Sir:

This Amendment under 37 C.F.R. §1.116 is submitted in response to the Final Office Action mailed January 14, 2002 in connection with the above-identified patent application. Also submitted is an Associate Power of Attorney document executed by Susan S. Rucker, who was given Power of Attorney for the Application as indicated in the Declaration filed September 30, 1998. Applicants respectfully request entry and consideration of this after-final Amendment and associated papers in view of the accompanying remarks.

IN THE CLAIMS

Please amend claim 34 as shown below and in Appendix 1, attached hereto.

34. The pharmaceutical composition according to claims 32 or 33, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.